Our aim was to evaluate the effects of enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients , such as lipoprotein ( a ) [ Lp ( a ) ] , soluble advanced glycation end products ( sRAGE ) , soluble CD40 ligand ( sCD40L ) and serum myeloperoxidase ( MPO ) .